TCT 245: Final 7-Year Results from the COMPARE-ABSORB Trial: Randomized Comparison of Bioresorbable Vascular Scaffold Versus Metallic Drug-Eluting Stent in Patients at High Risk of Restenosis. Detailed analysis of long lesions

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Amgen; AstraZenca; Abbott Vascular; Infraredx</li><li>Consultant Fee/Honoraria/Speaker’s Bureau - InfraredX; Novartis</li></ul>